Novel Allosteric Modulation of the Human 5-HT3A Receptor by the Clinically Used Drugs Piperazine and Hydroxyzine

Noelia Rodriguez Araujo, Jeremías Corradi, Ignacio Bergé, Cecilia Bouzat

Open source

DOI
10.1016/j.neuropharm.2026.111196
Published
2026-09
Container
Neuropharmacology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.neuropharm.2026.111196,
  title = {Novel Allosteric Modulation of the Human 5-HT3A Receptor by the Clinically Used Drugs Piperazine and Hydroxyzine},
  author = {Noelia Rodriguez Araujo and Jeremías Corradi and Ignacio Bergé and Cecilia Bouzat},
  year = {2026},
  journal = {Neuropharmacology},
  doi = {10.1016/j.neuropharm.2026.111196},
  url = {https://doi.org/10.1016/j.neuropharm.2026.111196}
}

RIS

TY  - JOUR
TI  - Novel Allosteric Modulation of the Human 5-HT3A Receptor by the Clinically Used Drugs Piperazine and Hydroxyzine
AU  - Noelia Rodriguez Araujo
AU  - Jeremías Corradi
AU  - Ignacio Bergé
AU  - Cecilia Bouzat
PY  - 2026
JO  - Neuropharmacology
DO  - 10.1016/j.neuropharm.2026.111196
UR  - https://doi.org/10.1016/j.neuropharm.2026.111196
ER  - 

APA

Araujo, N. R., Corradi, J., Bergé, I., & Bouzat, C. (2026). Novel Allosteric Modulation of the Human 5-HT3A Receptor by the Clinically Used Drugs Piperazine and Hydroxyzine. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2026.111196

Source records